Vertebral artery drug eluting stent

By designing vertebral artery drug-eluting stents with spiral structures and drug-coated, the stent flexibility and shortening rate in the treatment of vertebral artery stenosis in the prior art are solved, and the smooth expansion of the stent in the blood vessels is achieved and restenosis is reduced. The effect of risk.

CN221963842UActive Publication Date: 2024-11-08PUGAO MEDICAL TECH (NANJING) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202420194885.2
Authority / Receiving Office
CN · China
Patent Type
Utility models(China)
Current Assignee / Owner
Filing Date
2024-01-25
Publication Date
2024-11-08
Estimated Expiration
2034-01-25

AI Technical Summary

Technical Problem

In the prior art, when treating vertebral artery stenosis, drug treatment can only reduce thrombosis but cannot relieve vascular stenosis. The success rate of surgical procedures is low and the postoperative stenosis rate is high. There is a lack of vertebrae with low axial shortening rate and good axial compatibility. Arterial stent.

Method used

Design a vertebral artery drug-eluting stent, using a single-wave unit connected with a spiral structure and a connecting rod, combining an annular sine wave port and a variable diameter waveform connecting section, with low axial shortening rate and good radial support performance. And apply drugs that inhibit cell proliferation on the surface coating to prevent restenosis.

Benefits of technology

The superior flexibility and compliance of the stent is achieved, which can smoothly pass through the tortuosity of the brain, and improve the axial and radial shortening during the expansion process, reducing the risk of restenosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN221963842U_ABST
    Figure CN221963842U_ABST
Patent Text Reader

Abstract

The utility model discloses a vertebral artery medicine eluting stent, which belongs to the technical field of medical instruments and at least comprises a main body part, the main body part comprises at least one group of a plurality of single-wave units connected in series, and the plurality of single-wave units form a spiral structure. At least one group of two adjacent single-wave units in the axial direction are connected through a connecting rod; the stent with the spiral structure has excellent flexibility and compliance, and can smoothly pass through tortuous blood vessels of the brain; and meanwhile, axial shortening, radial shortening and dog bone phenomena of the stent in the expansion process can be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The utility model relates to the technical field of medical devices, in particular to a vertebral artery drug eluting stent. Background Art

[0002] Currently, atherosclerosis in the vertebral-basilar artery system is one of the main causes of posterior circulation stroke, and about one-fifth of posterior circulation strokes occur in the extracranial segment of the vertebral artery;

[0003] The drug treatment for vertebral artery stenosis mainly uses antiplatelet aggregation drugs or anticoagulants, but anticoagulation may cause coagulation disorders and lead to coagulation, and drug treatment can only reduce thrombosis and reduce the incidence of complications such as stroke, but cannot relieve vascular stenosis. Surgical treatment such as vertebral artery initial segment endarterectomy, even if performed by skilled physicians, has a very low success rate. Although angioplasty can significantly reduce the degree of stenosis in the vascular lumen, the postoperative restenosis rate is high due to the elastic retraction of the blood vessels. In view of the different defects of drugs, surgery, and PTA, intravascular stenting surgery for vertebral artery stenosis has begun to be widely studied and used. Among them, the flexibility of the vertebral artery stent and the axial and radial shortening rates have a significant impact on the accurate delivery of the stent. Therefore, how to design a vertebral artery stent with low axial shortening rate and good axial flexibility is a key problem to be solved in this field. Utility Model Content

[0004] One of the purposes of the present utility model is to provide a vertebral artery drug eluting stent, which has low axial shortening rate and good axial flexibility, and good radial support performance, and can solve at least one problem pointed out in the background technology.

[0005] A vertebral artery drug eluting stent comprises at least a main body, the main body comprises at least one group of multiple single-wave units connected in series, the multiple single-wave units form a spiral structure, and at least two adjacent single-wave units in the axial direction are connected by a connecting rod.

[0006] Preferably, the drug eluting stent further comprises at least one port portion connected to the main body portion, and the port portion is an annular sinusoidal waveform structure.

[0007] Preferably, the port portion is connected to the main body portion via a connecting section, and the connecting section is a variable-diameter wave-shaped structure.

[0008] Preferably, the connecting section and the main body are connected to the port portion via a connecting rod, and the connecting rod is in the shape of a straight rod.

[0009] Preferably, the single-wave unit comprises a long rod portion and a short rod portion, and the two ends of the connecting rod are respectively connected to the center positions of the two long rod portions.

[0010] Preferably, the connecting rod is corrugated.

[0011] Preferably, both ends of the main body portion are connected to the port portions, and center lines of the two port portions are parallel to each other.

[0012] Preferably, the drug eluting stent has at least one layer of drug coating.

[0013] Compared with the prior art, the beneficial effects of the present invention are as follows: the spiral structure stent designed by the present invention has excellent flexibility and compliance, and can smoothly pass through the tortuous blood vessels in the brain; at the same time, it can improve the axial shortening, radial shortening and dog bone phenomenon of the stent during expansion. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 This is a schematic diagram of the structure of the vertebral artery drug-eluting stent after deployment;

[0015] Figure 2 Schematic diagram of the structure of a single-wave unit.

[0016] Description of reference numerals:

[0017] 1-main part, 2-port part, 3-connecting section, 4-single wave unit, 41-long rod part, 42-short rod part, 5-connecting rod. DETAILED DESCRIPTION

[0018] A specific implementation of the present utility model is described in detail below in conjunction with the accompanying drawings, but it should be understood that the protection scope of the present utility model is not limited by the specific implementation mode.

[0019] Embodiment 1

[0020] like Figure 1 to Figure 2 As shown, a vertebral artery drug eluting stent provided by an embodiment of the utility model is made of cobalt-chromium alloy material, which at least includes a main body 1, and the main body 1 includes at least one group of multiple single-wave units 4 connected in series, and the multiple single-wave units connected in series form a spiral structure. Figure 1 The main body 1 includes two axially arranged spiral structures, and the two spiral structures are connected by a connecting rod 5. In addition, in order to improve the axial shortening of the stent during the expansion process, among multiple groups of two adjacent single-wave units 4 in the axial direction or among two adjacent single-wave units 4 in the axial direction, at least one group of two adjacent single-wave units 4 is connected by a connecting rod 5. Specifically, Figure 2As shown, the single-wave unit 4 includes a long rod portion 41 and a short rod portion 42, and the two ends of the connecting rod 5 are respectively connected to the center positions of the two long rod portions 41. In addition, in the circumferential direction, the connecting rods 5 are arranged at intervals. The purpose of this design is to make the drug-eluting stent have better axial flexibility;

[0021] In addition, the shape of the connecting rod 5 can be a straight rod, or a corrugated shape, an arc shape, a C shape, etc., which can be selected according to the actual required performance;

[0022] Embodiment 2

[0023] like Figure 1 As shown, this embodiment provides a vertebral artery drug eluting stent. Based on the above embodiment 1, the drug eluting stent also includes at least one port portion 2 connected to the main body portion 1, and the port portion 2 is a ring-shaped sinusoidal waveform structure; this embodiment takes two as an example, and the port portion 2 is connected to the main body portion 1 through a connecting section 3, and the connecting section 3 part adopts a variable diameter waveform structure (such as Figure 1 The connecting section 3 and the main body 1 are connected to the port part 2 through a connecting rod 5. The connecting rod 5 is a straight rod.

[0024] Embodiment 3

[0025] This embodiment provides a vertebral artery drug-eluting stent based on the first or second embodiment. The stent has at least one layer of drug coating, which is coated on the surface of the stent by spraying or dipping. The drug coating is selected to inhibit cell proliferation, which can effectively prevent vascular intimal hyperplasia and vascular smooth muscle cell proliferation, and prevent vertebral artery restenosis. The specific drug used is not limited in this embodiment, as long as it can achieve this effect, such as rapamycin;

[0026] Before spraying the drug coating, a base layer may be pre-installed on the stent, and the drug coating is sprayed on the base layer so that the drug can be better attached thereto.

[0027] It is obvious to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the present invention can be implemented in other specific forms without departing from the spirit and basic features of the present invention. Therefore, from any point of view, the embodiments should be regarded as exemplary and non-restrictive, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention. Any reference numeral in a claim should not be regarded as limiting the claim involved.

[0028] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.

Claims

1. A vertebral artery drug eluting stent, characterized in that: The drug eluting stent comprises at least a main body (1), wherein the main body (1) comprises at least one group of multiple single-wave units (4) connected in series, wherein the multiple single-wave units (4) form a spiral structure, and at least one group of two adjacent single-wave units (4) in the axial direction are connected via a connecting rod (5).

2. The vertebral artery drug eluting stent according to claim 1, characterized in that: The drug eluting stent further comprises at least one port portion (2) connected to the main body portion (1), wherein the port portion (2) is an annular sinusoidal waveform structure.

3. The vertebral artery drug eluting stent according to claim 2, characterized in that: The port portion (2) is connected to the main body portion (1) via a connecting section (3), and the connecting section (3) is a variable-diameter wave-shaped structure.

4. The vertebral artery drug eluting stent according to claim 3, characterized in that: The connecting section (3) and the main body (1) are connected to the port portion (2) via a connecting rod (5), and the connecting rod (5) is in the shape of a straight rod.

5. The vertebral artery drug eluting stent according to claim 1, characterized in that: The single-wave unit (4) comprises a long rod portion (41) and a short rod portion (42), and the two ends of the connecting rod (5) are respectively connected to the center positions of the two long rod portions (41).

6. A vertebral artery drug eluting stent according to claim 5, characterized in that: The connecting rod (5) is in a corrugated shape.

7. The vertebral artery drug eluting stent according to claim 2, characterized in that: Both ends of the main body part (1) are connected to the port parts (2), and the center lines of the two port parts (2) are parallel to each other.

8. The vertebral artery drug eluting stent according to claim 1, characterized in that: The drug eluting stent has at least one drug coating layer.